Haemonetics Corp. (HAE) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1155289,
    "name": "Haemonetics Corp.",
    "stock_name": "Haemonetics Corp.",
    "full_name": "Haemonetics Corp.",
    "name_url": "stocks-analysis/haemonetics-corp",
    "exchange": 207,
    "exchangecode": "NYS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "83.81",
    "chg": 1.9,
    "chgp": "2.32%",
    "dir": 1,
    "prev_price": "81.91",
    "mcapval": "2,606.39",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US4050241003",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "1.3 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/haemonetics-corp-1155289-207&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Haemonetics Corp. Experiences Revision in Its Stock Evaluation Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/haemonetics-corp-valuation-grade-downgraded-from-very-attractive-to-fair-3686188",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/HaemoneticsCorp_valuationdot_3686188.png",
        "date": "2025-11-10 15:39:43",
        "description": "Haemonetics Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, has recently adjusted its valuation, with its stock price at $68.36. Over the past year, the company has faced challenges, posting a -21.00% return, contrasting with the S&P 500's 12.65% gain. Key financial metrics indicate a competitive position despite stock volatility."
      },
      {
        "title": "Is Haemonetics Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-haemonetics-corp-overvalued-or-undervalued-3637232",
        "imagepath": "",
        "date": "2025-10-21 11:58:11",
        "description": "As of 17 October 2025, Haemonetics Corp. has moved from a fair to a very attractive valuation grade. The company is currently undervalued, supported by a P/E ratio of 22, an EV to EBITDA of 13.04, and a PEG ratio of 8.36. In comparison, its peers show more favorable valuations, with Haemonetics' P/E ratio significantly lower than Masimo Corp. at 179.74 and Bio-Rad Laboratories, Inc. at 16.20.\n\nDespite its attractive valuation, Haemonetics has underperformed against the S&P 500, with a year-to-date return of -35.63% compared to the index's gain of 13.30%. This stark contrast in performance highlights the potential for recovery and value realization in Haemonetics Corp...."
      },
      {
        "title": "Haemonetics Corp. Experiences Revision in Its Stock Evaluation Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/haemonetics-corp-sees-valuation-grade-upgrade-from-fair-to-very-attractive-3640691",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/HaemoneticsCorp_valuationdot_3640691.png",
        "date": "2025-10-20 16:11:13",
        "description": "Haemonetics Corp. has recently adjusted its valuation, showcasing a P/E ratio of 22 and a price-to-book value of 4.12. The company demonstrates a competitive position within the Pharmaceuticals & Biotechnology sector, particularly when compared to peers like Masimo Corp., Bio-Rad Laboratories, and Lantheus Holdings."
      },
      {
        "title": "Is Haemonetics Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-haemonetics-corp-overvalued-or-undervalued-3631642",
        "imagepath": "",
        "date": "2025-10-19 11:54:01",
        "description": "As of 17 October 2025, Haemonetics Corp. has moved from a fair to a very attractive valuation grade. The company appears undervalued, particularly when considering its P/E ratio of 22, which is significantly higher than the peer average of 16.35, and its EV to EBITDA ratio of 13.04 compared to the peer average of 10.38. Additionally, the PEG ratio stands at 8.36, indicating a potential mispricing relative to growth expectations.\n\nIn comparison to its peers, Haemonetics Corp. shows a stronger return on equity (ROE) of 18.58% and return on capital employed (ROCE) of 12.30%, which are favorable indicators of operational efficiency. Notably, Masimo Corp. has a much higher P/E ratio of 179.74, while Bio-Rad Laboratories, Inc. has a P/E of 16.20, reinforcing Haemonetics' relative attractiveness. Despite recent underperformance with a year-to-date return of -35.63% versus the S&P 500's 13.30%, the company's strong..."
      },
      {
        "title": "Is Haemonetics Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-haemonetics-corp-technically-bullish-or-bearish-3545682",
        "imagepath": "",
        "date": "2025-09-20 19:16:17",
        "description": "As of 15 August 2025, the technical trend for Haemonetics Corp. has changed from mildly bearish to bearish. The current technical stance is bearish with a strong indication from multiple indicators: the MACD is bearish on both weekly and monthly time frames, Bollinger Bands are bearish, and moving averages are also bearish on a daily basis. The KST and Dow Theory both reflect bearish sentiment on weekly and monthly scales. Additionally, the OBV shows a mildly bearish stance. \n\nHaemonetics has underperformed significantly against the S&P 500 across multiple periods, with a year-to-date return of -34.49% compared to the S&P 500's 12.22%, and a 1-year return of -32.35% versus 17.14% for the index...."
      },
      {
        "title": "Is Haemonetics Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-haemonetics-corp-overvalued-or-undervalued-3542371",
        "imagepath": "",
        "date": "2025-09-20 17:51:13",
        "description": "As of 25 August 2025, the valuation grade for Haemonetics Corp. has moved from attractive to very attractive, indicating a stronger position in the market. The company appears to be undervalued, especially when considering its P/E ratio of 22, which is significantly higher than the peer average of 16.35 for companies like Masimo Corp. and Bio-Rad Laboratories, Inc. Additionally, Haemonetics has an EV/EBITDA ratio of 13.04, which is lower than the industry average, suggesting potential for growth.\n\nIn comparison to its peers, Haemonetics Corp. maintains a favorable ROE of 18.58% and ROCE of 12.30%, both of which highlight its efficiency in generating returns relative to its equity and capital employed. Despite this positive valuation outlook, the stock has underperformed against the S&P 500, with a year-to-date return of -34.49% compared to the index's 12.22%, indicating that while the company may be fundame..."
      }
    ],
    "total": 11,
    "sid": "1155289",
    "stock_news_url": "https://www.marketsmojo.com/news/haemonetics-corp-1155289"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Haemonetics Corp. Experiences Revision in Its Stock Evaluation Amid Market Dynamics

2025-11-10 15:39:43

Haemonetics Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, has recently adjusted its valuation, with its stock price at $68.36. Over the past year, the company has faced challenges, posting a -21.00% return, contrasting with the S&P 500's 12.65% gain. Key financial metrics indicate a competitive position despite stock volatility.

Is Haemonetics Corp. overvalued or undervalued?

2025-10-21 11:58:11

As of 17 October 2025, Haemonetics Corp. has moved from a fair to a very attractive valuation grade. The company is currently undervalued, supported by a P/E ratio of 22, an EV to EBITDA of 13.04, and a PEG ratio of 8.36. In comparison, its peers show more favorable valuations, with Haemonetics' P/E ratio significantly lower than Masimo Corp. at 179.74 and Bio-Rad Laboratories, Inc. at 16.20. Despite its attractive valuation, Haemonetics has underperformed against the S&P 500, with a year-to-date return of -35.63% compared to the index's gain of 13.30%. This stark contrast in performance highlights the potential for recovery and value realization in Haemonetics Corp....

Haemonetics Corp. Experiences Revision in Its Stock Evaluation Amid Market Dynamics

2025-10-20 16:11:13

Haemonetics Corp. has recently adjusted its valuation, showcasing a P/E ratio of 22 and a price-to-book value of 4.12. The company demonstrates a competitive position within the Pharmaceuticals & Biotechnology sector, particularly when compared to peers like Masimo Corp., Bio-Rad Laboratories, and Lantheus Holdings.

Is Haemonetics Corp. overvalued or undervalued?

2025-10-19 11:54:01

As of 17 October 2025, Haemonetics Corp. has moved from a fair to a very attractive valuation grade. The company appears undervalued, particularly when considering its P/E ratio of 22, which is significantly higher than the peer average of 16.35, and its EV to EBITDA ratio of 13.04 compared to the peer average of 10.38. Additionally, the PEG ratio stands at 8.36, indicating a potential mispricing relative to growth expectations. In comparison to its peers, Haemonetics Corp. shows a stronger return on equity (ROE) of 18.58% and return on capital employed (ROCE) of 12.30%, which are favorable indicators of operational efficiency. Notably, Masimo Corp. has a much higher P/E ratio of 179.74, while Bio-Rad Laboratories, Inc. has a P/E of 16.20, reinforcing Haemonetics' relative attractiveness. Despite recent underperformance with a year-to-date return of -35.63% versus the S&P 500's 13.30%, the company's strong...

Is Haemonetics Corp. technically bullish or bearish?

2025-09-20 19:16:17

As of 15 August 2025, the technical trend for Haemonetics Corp. has changed from mildly bearish to bearish. The current technical stance is bearish with a strong indication from multiple indicators: the MACD is bearish on both weekly and monthly time frames, Bollinger Bands are bearish, and moving averages are also bearish on a daily basis. The KST and Dow Theory both reflect bearish sentiment on weekly and monthly scales. Additionally, the OBV shows a mildly bearish stance. Haemonetics has underperformed significantly against the S&P 500 across multiple periods, with a year-to-date return of -34.49% compared to the S&P 500's 12.22%, and a 1-year return of -32.35% versus 17.14% for the index....

Is Haemonetics Corp. overvalued or undervalued?

2025-09-20 17:51:13

As of 25 August 2025, the valuation grade for Haemonetics Corp. has moved from attractive to very attractive, indicating a stronger position in the market. The company appears to be undervalued, especially when considering its P/E ratio of 22, which is significantly higher than the peer average of 16.35 for companies like Masimo Corp. and Bio-Rad Laboratories, Inc. Additionally, Haemonetics has an EV/EBITDA ratio of 13.04, which is lower than the industry average, suggesting potential for growth. In comparison to its peers, Haemonetics Corp. maintains a favorable ROE of 18.58% and ROCE of 12.30%, both of which highlight its efficiency in generating returns relative to its equity and capital employed. Despite this positive valuation outlook, the stock has underperformed against the S&P 500, with a year-to-date return of -34.49% compared to the index's 12.22%, indicating that while the company may be fundame...

View All News